Clinical Trial Update: Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease [Phase 2]

View source ↗

Summary

Phase 2 two-period crossover study to demonstrate pharmacokinetic comparability of subcutaneous ianalumab administered with a 2 mL auto-injector/2 mL pre-filled…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis
• Sjögren Syndrome
• Systemic Lupus Erythematosus

Drugs mentioned

• Ianalumab (ianalumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sjögrens Disease, Systemic Lupus Erythematosus | Phase 2 | Status: ACTIVE_NOT_RECRUITING